Bassetti, Matteo http://orcid.org/0000-0002-2004-3724
Vena, Antonio
Meroi, Marco
Cardozo, Celia
Cuervo, Guillermo
Giacobbe, Daniele Roberto
Salavert, Miguel
Merino, Paloma
Gioia, Francesca
Fernández-Ruiz, Mario
López-Cortés, Luis Eduardo
Almirante, Benito
Escolà-Vergé, Laura
Montejo, Miguel
Aguilar-Guisado, Manuela
Puerta-Alcalde, Pedro
Tasias, Mariona
Ruiz-Gaitán, Alba
González, Fernando
Puig-Asensio, Mireia
Marco, Francesc
Pemán, Javier
Fortún, Jesus
Aguado, Jose Maria
Soriano, Alejandro
Carratalá, Jordi
Garcia-Vidal, Carolina
Valerio, Maricela
Sartor, Assunta
Bouza, Emilio
Muñoz, Patricia
Funding for this research was provided by:
Instituto de Salud Carlos III (PI15/00744)
Article History
Received: 19 October 2019
Accepted: 17 February 2020
First Online: 26 March 2020
Ethics approval and consent to participate
: The study was approved by the local institutional review boards, and written patient consent was not required because of observational nature of this study.
: Not applicable
: MB has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, AstraZeneca, Bayer, Basilea, Cidara, Gilead, Menarini, MSD, Paratek, Pfizer, Roche, The Medicine Company, Shionogi, Tetraphase, VenatoRx, and Vifor. CGV has received honoraria for talks on behalf of Gilead Science, Merck Sharp and Dohme, Novartis, Pfizer, Jannsen, as well as a grant from Gilead Science. JC has received honoraria for lectures from Gilead and Merck Sharp and Dohme. MS has received honoraria for participating in meetings, forums and consultancies, as well as for having given conferences for MSD, Pfizer, Janssen, Angelini, ERN, Gilead, and Astellas Ph. He has also received grants and scholarships for research and teaching, which were administered through La Fe Sanitary Research Institute (IIS-LA FE) and companies such as ViiV, Janssen, MSD. LELC has served as speaker for Merck, Sharp, and Dohme. Angelini has received research support from Novartis and served as trainer for Merck, Sharp, and Dohme. PM is a consultant and/or speaker for Astellas, Gilead, Merck, Novartis, and Pfizer, and T2 Biosystems. JF has been advisor/consultant and has received honoraria for talks on behalf of Gilead Sciences, Merck, Sharp, and Dohme, Pfizer, and Astellas Pharma; MFR has received honoraria for talks on behalf of Gilead Science, Astellas, and Pfizer. JMA has received honoraria for speaking at symposia organized on behalf of Pfizer, Astellas, Merck, Sharp, & Dohme (MSD). Angelini has sat on advisory boards for antifungal agents on behalf of Pfizer, Astellas, MSD, Angelini, and Gilead Science.